Microglial modulation of neurocircuits in HIV/cocaine comorbidity

Active Grant Awarded Last action

Award ID
R01DA059310
Recipient
Awarding agency
Obligated
$2,440,262

Award facts

Completion date 65% complete
Originally
Place of performance
Columbia, SC 29208, USA

Award details come from USAspending.gov.

Description

Abstract
Despite the success of combination antiretroviral therapy (CART), a significant proportion of infected individuals exhibiting neurocognitive decline, and a prior history of substance use disorder (SUD) may result in an exacerbated rate of decline. Thus, prior drug history may be clinically significant in the treatment of neurological HIV-1 infection. The specific aims of the project are: 1) to define the dendritic "spine- targeted" - microglial interactions which produce HIV-1/psychostimulant-induced synaptodendritic loss and spine dysmorphology. Dendritic spine loss is a key pathology of hand; however, the underlying mechanisms remain largely uncharacterized. We will investigate whether HIV-infected microglia play a key role in spine loss/dysmorphology using an in vitro HIV infection model and psychostimulant drug exposures in SEX- specified brain cell cultures. 2) to establish whether a history of psychostimulant abuse drives an accelerated progression of microglial dysfunction and dendritic spine alterations following HIV infection. Dopamine will be assessed both prior to and after ecohiv-infection in animals with or without a history of cocaine self-administration. The mechanisms by which HIV-infected microglia produce dopaminergic circuit dysfunction will be critically tested using proviral gene excision techniques; CART, and sabv are integral factors of the design. 3) to establish executive function "choice" deficits in ecohiv-infected animals, and the role of microglial HIV infection, following psychostimulant self-administration. We will establish prior drug history and HIV-1 infection as variables that influence the effect of fronto-striatal circuit dysregulation on choice behavior, thereby identifying factors that may exacerbate resistance to treatment. We will examine synaptodendritic integrity in pyramidal neurons of the medial prefrontal cortex (MPFC) and medium spiny neurons (MSN) of the nucleus accumbens given their sensitivity to drug history and/or HIV-1 infection. Targeted proviral gene excision of HIV from microglial cells will be used to determine the role of infected microglial cells in executive function deficits. Thus, this proposal addresses two key questions regarding neurohiv - 1) does a history of drug dependence alter the progression and clinical outcomes of HIV-1- associated neurocognitive disorders? And 2) how do substances of abuse and HIV interact to produce dendritic spine alterations, one of the key neuropathologies of neurohiv in the current CART ERA? The program goal is to identify how microglial HIV infections produce synaptodendritic loss; knowledge that will lead to novel therapeutic strategies for restoring fronto-striatal circuitry.

Transactions

Action Obligated Date
Amendment $508,540
Amendment $0
Amendment $649,619
Amendment $0
Amendment $0
Amendment -$41,273
Amendment $0
Amendment $65,365
Amendment $588,277
Original award $669,734

Quick answers

Who received award R01DA059310?

R01DA059310 was awarded to University Of South Carolina by National Institute on Drug Abuse (National Institutes of Health) on May 30, 2023.

How much is award R01DA059310 worth?

$2,440,262 has been obligated on R01DA059310.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award